India’s drug price regulator has reset the maximum retail price of 543 anti-cancer brands from 9 November 2026, cutting one Anastrozole pack from ₹695.76 to ₹73 and pushing the squeeze onto the trade chain.
The National Pharmaceutical Pricing Authority, under the Department of Pharmaceuticals, published the list on 28 October 2026 and said it reflects prices submitted by companies up to 27 October. It described the 17 October trade margin rationalisation of 137 non-scheduled anti-cancer drugs as a step "to address excessive trade margins", according to its release.
The gap matters because the printed price is the ceiling for everyone downstream. A pack that listed at ₹695.76 now lists at ₹73, so distributors, stockists, retail pharmacies and hospital pharmacies that earn a margin on the printed price lose rupees on every pack they move.
The larger packs show the scale. Abbott Healthcare’s Bevacizab, a 100 mg/4 ml vial, goes from ₹21,767.70 to ₹5,930.13. RPG Life Sciences’ Debrumab, a 60 mg Denosumab injection, goes from ₹22,031.25 to ₹5,941, and its Fulbreca, a 50 mg Fulvestrant injection, from ₹26,072.16 to ₹5,491. Hetero Healthcare’s Fludanox goes from ₹14,235 to ₹2,432, and Dr. Reddy’s Laboratories’ Azacytin from ₹6,337 to ₹1,495.04.
Oral drugs are cut less sharply but still deeply. Natco Pharma’s Dasanat 20, a 60-tablet pack of Dasatinib, goes from ₹2,812.50 to ₹1,085.93. RPG’s Enuta, an Enzalutamide capsule, goes from ₹6,578.20 to ₹2,232, and Neon Laboratories’ Erlib, an Erlotinib tablet, from ₹4,637.45 to ₹2,008. Across the examples the cuts run roughly 50 to 90 per cent.
The scope is wider than the first list. The 137 drugs covered by the October rationalisation include immunotherapy medicines used in over 20 types of cancer, Denosumab for breast and prostate cancer patients, Pegfilgrastim to prevent neutropenia in cancer patients, and Bevacizumab, approved for colon, ovarian and cervical cancers. The authority says the list is updated as manufacturers submit revised prices, so 543 is a first count rather than a ceiling.
The first loss falls on the trade. A margin set as a share of a much lower price is a much smaller sum on each pack, and high-ticket oncology packs were where the absolute spread was largest, including the spread hospital pharmacies earn on injectables. The release does not say how stock bought at the old MRPs is to be handled, which leaves relabelling and write-down questions for manufacturers and the trade between now and 9 November.
The makers are the second layer. Brand-heavy oncology companies face a trade-off between volume and price, and biosimilar and generic makers gain relative to them. The brand owners named in the release are RPG Life Sciences, Dr. Reddy’s Laboratories, Natco Pharma, Hetero Healthcare, Abbott Healthcare and Neon Laboratories.
The owners behind one of them can be sized. Natco’s promoters hold 49.42 per cent as of the June 2026 quarter, worth ₹7,086.2 crore at the close of 12 October 2026, down 0.14 percentage points over the year. V C Nannapaneni is the largest single holder at 15.66 per cent, followed by Time Cap Pharma Labs at 9.59 per cent, Venkata Satya Swathi Kantamani at 8.90 per cent and Natsoft Information Systems at 8.81 per cent.
The institutions hold the rest of the exposure. Foreign institutions own 16.99 per cent of Natco, worth ₹2,436.1 crore and up 1.48 percentage points. Domestic institutions hold 5.62 per cent (₹805.8 crore), insurance companies 3.64 per cent (₹521.9 crore) and mutual funds 1.92 per cent (₹275.3 crore). Life Insurance Corporation of India holds 2.24 per cent. Foreign money rose into a stock whose flagship oncology pack has just been repriced, which makes the next filings worth reading.
Still, the macro effect is small. The segment is narrow, so the pull on the wholesale price index for pharmaceuticals and on consumer health prices is tiny. Nor does the release give any company revenue or margin figure, so how much of the cut falls on the trade and how much on manufacturers is not stated, and lower-priced drugs carry a supply risk if the trade stops stocking them.
The next fixed date is 9 November 2026, when the new MRPs take effect. Between now and then the authority’s list is updated as each manufacturer files, and each batch changes the map of who carries the cut.



